Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial

This 2026 trial examined whether genetic information could improve antidepressant prescribing. It enrolled 1,460 adults and children and used publicly available prescribing guidance. Among participants with actionable drug-metabolism results, genetic guidance did not significantly improve depression symptoms at three months compared with usual care. At six months, remission was higher in the genetically guided group—48.3% compared with 39.4%. The findings suggest a possible longer-term benefit while leaving questions about durability and broader application. The research includes Vanderbilt and Meharry affiliations, giving it additional Tennessee relevance.